OrbiMed’s Pfizer PFE Stock Holding History

OrbiMed’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-263,500	Closed	-$10.8M	–	132
2019 Q2	$10.8M	Buy	+263,500	New	+$10.5M	0.17%	92

Other funds holding PFE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return

OrbiMed's PFE Position: Q1 2026 in Review

OrbiMed increased its Pfizer (PFE) stake by 18% in Q1 2026, buying an estimated $7.82M and bringing the position to 1,946,500 shares worth $54.7M. The position accounts for 1.08% of the portfolio, ranked #28.

OrbiMed first reported a position in PFE in Q2 2013 and has held it in 33 quarters since. The position peaked at $202M in Q1 2022. 2,939 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

OrbiMed held 1,946,500 shares of Pfizer worth $54.7M as of Q1 2026.
OrbiMed bought 293,600 Pfizer shares in Q1 2026, an estimated $7.82M.
Pfizer made up 1.08% of OrbiMed's portfolio in Q1 2026, its #28 holding.
OrbiMed first reported a position in Pfizer in Q2 2013 and has held it in 33 quarters since.
OrbiMed's Pfizer position peaked at $202M in Q1 2022.
2,939 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on OrbiMed's 13F filing for Q1 2026, filed 15 May 2026.